#Nsclc

Diseases & TreatmentsMedicalXpress

Smoking cessation after NSCLC diagnosis cuts mortality risk

(HealthDay)—For patients with non-small cell lung cancer (NSCLC), smoking cessation after diagnosis is associated with a reduced risk for all-cause mortality, cancer-specific mortality, and disease progression, according to a study published online July 27 in the Annals of Internal Medicine. Mahdi Sheikh, M.D., Ph.D., from the International Agency for Research...
Picture for Smoking cessation after NSCLC diagnosis cuts mortality risk
CancerNature.com

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer

Conventional chemotherapy is still of great utility in oncology and rationally constructing combinations with it remains a top priority. Drug-induced mitochondrial apoptotic priming, measured by dynamic BH3 profiling (DBP), has been shown in multiple cancers to identify drugs that promote apoptosis in vivo. We therefore hypothesized that we could use DBP to identify drugs that would render cancers more sensitive to conventional chemotherapy. We found that targeted agents that increased priming of non-small cell lung cancer (NSCLC) tumor cells resulted in increased sensitivity to chemotherapy in vitro. To assess whether targeted agents that increase priming might enhance the efficacy of cytotoxic agents in vivo as well, we carried out an efficacy study in a PC9 xenograft mouse model. The BH3 mimetic navitoclax, which antagonizes BCL-xL, BCL-w, and BCL-2, consistently primed NSCLC tumors in vitro and in vivo. The BH3 mimetic venetoclax, which electively antagonizes BCL-2, did not. Combining navitoclax with etoposide significantly reduced tumor burden compared to either single agent, while adding venetoclax to etoposide had no effect on tumor burden. Next, we assessed priming of primary patient NSCLC tumor cells on drugs from a clinically relevant oncology combination screen (CROCS). Results confirmed for the first time the utility of BCL-xL inhibition by navitoclax in priming primary NSCLC tumor cells and identified combinations that primed further. This is a demonstration of the principle that DBP can be used as a functional precision medicine tool to rationally construct combination drug regimens that include BH3 mimetics in solid tumors like NSCLC.
Picture for Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
CancerNature.com

Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies

The immune-related adverse events associated with treatment with immune checkpoint inhibitors result in significant morbidity for patients as well as considerable cost to the health-care system, and can limit the use of these beneficial drugs. Understanding the mechanisms of these side effects and how they can be separated from the antitumour effects of immune checkpoint inhibitors, as well as identifying biomarkers that predict the development of immune-related toxicities, will facilitate the conduct of trials to limit their onset and improve patient outcomes. In this Review, we discuss the different types of immune-related adverse events and how their treatment and identification of possible predictive biomarkers may shed light on their mechanisms, and describe possible strategies and targets for prophylactic and therapeutic intervention to mitigate them.
Picture for Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
TRENDING TOPICS
Canceroutsourcing-pharma.com

BMS, BridgeBio partner to study drug combo for lung cancer

The two pharma firms will partner to study the efficacy of Opdivo, paired with a SHP2 inhibitor, to treat non-small cell lung cancer with KRAS mutations. Bristol Myers Squibb (BMS) will work with commercial-stage biopharmaceutical company BridgeBio Pharma to evaluate a study combining Opdivo (nivolumab) and BBP-398 (an SHP2 inhibitor). The study is designed to test the effectiveness and safety of the dual treatment in patients with advanced solid non-small cell lung cancer (NSCLC).
New Haven, CTdocwirenews.com

Adding Ipilimumab to Nivolumab No Better in Pretreated Squamous NSCLC

For patients with advanced, chemotherapy-pretreated, immune checkpoint inhibitor-naive squamous (Sq) non-small cell lung cancer (NSCLC), ipilimumab added to nivolumab does not improve outcomes versus nivolumab alone, according to a study published online July 15 in JAMA Oncology. Scott N. Gettinger, M.D., from the Yale Cancer Center in New Haven, Connecticut,...
CancerManaged Healthcare Executive

Never Too Late To Quit: Smoking Cessation Pays Off for NSCLC Patients

Study shows that nonsmall cell lung cancer patients who smoke but quit after their diagnosis have better overall survival, progression-free survival than patients who continue to smoke. Say a treatment drug for nonsmall cell lung cancer (NSCLC) increased overall survival by 21.6 months and progression-free survival by the same amount...
Cancertargetedonc.com

Roundtable Discussion: Participants Reflect on Sending Blood- Vs Tissue-Based Tests in NSCLC

During a Targeted Oncology Case-Based Roundtable event, Grace K. Dy, MD and 9 other physicians discussed molecular testing for patients with non–small cell lung cancer. During a Targeted Oncology Case-Based Roundtable event, Grace K. Dy, MD, the chief, of Thoracic Oncology, and associate professor of Oncology in Department of Medicine at Roswell Park Comprehensive Cancer Center, and 9 other physicians discussed molecular testing for patients with non–small cell lung cancer (NSCLC).
Medical & Biotechbiospace.com

Bristol Myers Seeks Redeeming Combination for Struggling Checkpoint Inhibitor

California-based biopharmaceutical firm BridgeBio Pharma has announced a funding collaboration with Bristol Myers Squibb to evaluate a potential treatment for patients with difficult-to-treat cancers. Under the terms of the agreement, the companies will co-finance a clinical study that will test the combination of SHP2 inhibitor BBP-398 and OPDIVO (nivolumab) in...
CancerNature.com

FDG-PET predicts bone invasion and prognosis in patients with oral squamous cell carcinoma

18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is widely used for tumor staging. This study sought to determine the relationship of preoperative primary tumor SUVmax (tSUVmax) with the clinicopathological features of patients with OSCC and to compare the prognostic ability of tSUVmax with that of other recurrence factors. Data of 340 patients with OSCC who were diagnosed, treated, and followed up at the Changhua Christian Hospital were retrospectively analyzed. Only patients with OSCC arising from gingiva, palate, floor of the mouth, and retromolar trigone and those who had received preoperative FDG-PET within 2 weeks before surgery were included. tSUVmax value > 9.2 was the strong predictor of bone invasion (area under the receiver operating characteristic curve, 0.844). tSUVmax value > 7.2 showed a strong association with advanced pathological T stage and recurrence factors and was associated with poor survival; tSUVmax > 7.2 showed stronger predictive power for poor disease-free survival (DFS) than pT stage and the other recurrence factors related to primary tumor. FDG-PET can be a useful supplement to contrast-enhanced computed tomography or contrast-enhanced magnetic resonance imaging for diagnosing bone invasion by OSCC. The tSUVmax value was an independent predictor of DFS in this study.
CancerMedPage Today

Going Smoke-Free at Lung Cancer Diagnosis May Extend Lives

Going smoke-free after a diagnosis of early-stage non-small cell lung cancer (NSCLC) significantly reduced risks of overall and disease-specific mortality, according to a prospective study. Over an average follow-up of 7 years, smoking cessation was associated with a 33% decreased risk of all-cause mortality (HR 0.67, 95% CI 0.53-0.85), a...
Stocksmayfieldrecorder.com

Mersana Therapeutics (NASDAQ:MRSN) Rating Increased to Hold at Zacks Investment Research

According to Zacks, “Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company’s product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. “. A number of other research...
Cancerauntminnie.com

Quitting smoking slows early lung cancer progression

July 26, 2021 -- People who quit smoking after being diagnosed with early-stage non-small cell lung cancer (NSCLC) have slower disease progression and lower mortality rates, according to a study published July 26 in the Annals of Internal Medicine. More than 80% of patients with NSCLC have a history of...
Cancercancernetwork.com

Jonathan Spicer, MD, PhD, Discusses Multidisciplinary Communication for Treating Resectable NSCLC With Neoadjuvant Immunotherapy

CancerNetwork® sat down with Jonathan Spicer, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about how communication across a multidisciplinary team was necessary to the success of neoadjuvant immunotherapy administration in CheckMate 816. At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork®...
Stockscom-unik.info

TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares Sold by Hillhouse Capital Advisors LTD.

Hillhouse Capital Advisors LTD. cut its holdings in shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) by 87.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,577 shares of the company’s stock after selling 283,326 shares during the quarter. Hillhouse Capital Advisors LTD.’s holdings in TCR2 Therapeutics were worth $874,000 at the end of the most recent reporting period.
CancerPosted by
TheStreet

Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data In Low Grade Serous Ovarian Cancer Selected For A Mini Oral Presentation At The European Society Of Medical Oncology Congress 2021

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that an abstract detailing updated results from the ongoing Phase 1/2 FRAME study investigating VS-6766, the Company's RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low grade serous ovarian cancer (LGSOC) has been selected for a mini oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress 2021, taking place virtually September 16-21, 2021.
Medical & BiotechStreetInsider.com

BridgeBio Pharma Inc. (BBIO) Clinical Collaboration with Bristol Myers Squibb (BMY) to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO in Advanced Solid Tumors wi

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio),"¯a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced a non-exclusive, co-funded clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with OPDIVO® (nivolumab) in patients with advanced solid tumors with KRAS mutations with the hope of providing an effective new treatment option for patients with difficult-to-treat cancers.
YOU MAY ALSO LIKE